Compare Gilead Sciences, Inc. (GILD) vs Lowe`s Companies Inc (LOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Lowe`s Companies Inc — how do they compare? Gilead Sciences, Inc. trades at $134.65 (market cap $163.51B), while Lowe`s Companies Inc trades at $215.04 (market cap $117.56B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | LOW | |
|---|---|---|
Market Cap | $163.51B | $117.56B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $287.39 |
52-Week Low | $108.22 | $206.62 |
Enterprise Value | $178.05B | $159.31B |
Dividend Yield | 2.49% | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Lowe's Companies (LOW) trades at $213.81, up 2.94% on the day, with a bearish technical signal but strong analyst consensus. Recent earnings beats and a 7.51% net income margin highlight operational strength, though revenue has declined from $96.2B in 2022 to $83.7B in 2025. The stock shows support near $205 and resistance at $215, with a consensus price target of $260.88 implying 22% upside. Dividend growth remains a key attraction, with the quarterly payout rising to $1.25.
LOW offers value with a P/E of 17.72 and bullish analyst sentiment (60.79% buy ratings), but faces risks from high debt levels and competitive pressures. The outlook hinges on execution in the professional segment and interest rate sensitivity, with near-term volatility expected around Q2 earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →
